simendan has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Güven, BB; Özkan, S; Suakıtıcı, S; Tanoglu, A | 1 |
| Cai, D; Cohen-Solal, A; Deye, N; Kivikko, M; Laribi, S; Laterre, PF; Mebazaa, A; Nikolaou, M; Parissis, J; Paugam-Burtz, C; Poder, P; Pohjanjousi, P; Seronde, MF; Yilmaz, MB | 1 |
| Häkkinen, S; Kantele, S; Kivikko, M; Pentikäinen, PJ; Puttonen, J; Ramela, M; Ruck, A | 1 |
1 trial(s) available for simendan and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Topics: Acetylation; Area Under Curve; Biotransformation; Female; Half-Life; Humans; Hydrazones; Injections, Intravenous; Liver Diseases; Male; Middle Aged; Protein Binding; Pyridazines; Simendan; Vasodilator Agents | 2008 |
2 other study(ies) available for simendan and Liver Dysfunction
| Article | Year |
|---|---|
A combination of levosimendan and N-Acetylcysteine shows significant favorable efficacy on experimental liver ischemia/reperfusion injury.
Topics: Acetylcysteine; Animals; Liver; Liver Diseases; Oxidative Stress; Protective Agents; Rats; Reperfusion Injury; Simendan | 2021 |
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.
Topics: Acute Disease; Aged; Alkaline Phosphatase; Cardiotonic Agents; Cholestasis; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Liver Diseases; Liver Function Tests; Male; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Transaminases | 2013 |